Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael A Panzara

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Biologics : Targets & Therapy|August 27, 2009
Natalizumab for the treatment of relapsing multiple sclerosisRichard A Rudick, Michael A Panzara
The New England Journal of Medicine|June 11, 2005
Natalizumab and progressive multifocal leukoencephalopathyBurt Adelman, Alfred Sandrock, Michael A Panzara
Current Protocols in Immunology|April 25, 2008
Evaluating human T cell receptor gene expression by PCREmanuela Gussoni, Michael A Panzara, Lawrence Steinman
The New England Journal of Medicine|July 4, 2008
More on melanoma with transdifferentiationMichael A Panzara, Carmen Bozic, Alfred W Sandrock
Annals of Neurology|October 3, 2009
Natalizumab and central nervous system lymphoma: no clear associationCarmen Bozic, Julia LaGuette, Michael A Panzara, et al.
Statistics in Medicine|May 7, 2021
Bayesian adaptive design for clinical trials in Duchenne muscular dystrophyStephen L Lake, Melanie A Quintana, Kristine Broglio, et al.
Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging|February 21, 2003
Diffusion-weighted magnetic resonance imaging abnormalities in Bartonella encephalopathyAneesh B Singhal, Michael C Newstein, Ronald Budzik, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|August 23, 2017
Teriflunomide slows BVL in relapsing MS: A reanalysis of the TEMSO MRI data set using SIENAErnst-Wilhelm Radue, Till Sprenger, Laura Gaetano, et al.
The New England Journal of Medicine|March 3, 2006
Natalizumab plus interferon beta-1a for relapsing multiple sclerosisRichard A Rudick, William H Stuart, Peter A Calabresi, et al.
Neurology|October 14, 2016
Alemtuzumab improves preexisting disability in active relapsing-remitting MS patientsGavin Giovannoni, Jeffrey A Cohen, Alasdair J Coles, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Biologics : Targets & Therapy|August 27, 2009
Natalizumab for the treatment of relapsing multiple sclerosisRichard A Rudick, Michael A Panzara
The New England Journal of Medicine|June 11, 2005
Natalizumab and progressive multifocal leukoencephalopathyBurt Adelman, Alfred Sandrock, Michael A Panzara
Current Protocols in Immunology|April 25, 2008
Evaluating human T cell receptor gene expression by PCREmanuela Gussoni, Michael A Panzara, Lawrence Steinman
The New England Journal of Medicine|July 4, 2008
More on melanoma with transdifferentiationMichael A Panzara, Carmen Bozic, Alfred W Sandrock
Annals of Neurology|October 3, 2009
Natalizumab and central nervous system lymphoma: no clear associationCarmen Bozic, Julia LaGuette, Michael A Panzara, et al.
Statistics in Medicine|May 7, 2021
Bayesian adaptive design for clinical trials in Duchenne muscular dystrophyStephen L Lake, Melanie A Quintana, Kristine Broglio, et al.
Journal of Neuroimaging : Official Journal of the American Society of Neuroimaging|February 21, 2003
Diffusion-weighted magnetic resonance imaging abnormalities in Bartonella encephalopathyAneesh B Singhal, Michael C Newstein, Ronald Budzik, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|August 23, 2017
Teriflunomide slows BVL in relapsing MS: A reanalysis of the TEMSO MRI data set using SIENAErnst-Wilhelm Radue, Till Sprenger, Laura Gaetano, et al.
The New England Journal of Medicine|March 3, 2006
Natalizumab plus interferon beta-1a for relapsing multiple sclerosisRichard A Rudick, William H Stuart, Peter A Calabresi, et al.
Neurology|October 14, 2016
Alemtuzumab improves preexisting disability in active relapsing-remitting MS patientsGavin Giovannoni, Jeffrey A Cohen, Alasdair J Coles, et al.
Pageof 3